dulaglutide vs tirzepatide Shows Stronger Kidney Protection Than in Type 2 Diabetes | Yasir Elamin posted on the topic Demonstrating Preservation of 50% Efficacy

Tirzepatide is a dual GIP and GLP-1 receptor agonist approved by the FDA for type 2 diabetes and chronic weight management

Last reviewed: June 25, 2026 Last updated: June 25, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations

GLP-1 exposure may accelerate or worsen thyroid malignancy risk in this population

2023 Jan 19

He critiques modern lifestyles for segregation and disconnection, contrasting with communal cultures that thrive

Do you accept customized products